Skip to main content
Latest news
Browse specialties
Breast cancer Genitourinary cancers Lung & thoracic cancers
In focus
Next-generation sequencing: Emerging biomarkers in thyroid and NSCLCs ctDNA and bladder cancer: Current understanding and beyond ROS1 fusion-positive NSCLC NSCLC driver mutations: Discussing the importance of RET, ALK and ROS1 alterations in NSCLC Early-stage NSCLC management: Surgery, targeted treatment and immunotherapy ALK fusion-positive NSCLC: International approaches to management RET fusion-positive NSCLC: Informing on the use of pralsetinib for patients with RET fusion-positive, advanced NSCLC COVID-19 & cancer
Conferences
SABCS 2022 ESMO 2022 2022 ASCO Annual Meeting
About us
Medicine Matters Oncology
EXTENDED SEARCH
Top

22-12-2015 | Breast cancer | Article

The Epidemiology of Male Breast Cancer

Journal: Current Oncology Reports

Authors: Raina M. Ferzoco, Kathryn J. Ruddy

Publisher: Springer US

Login to get access

Abstract

Male breast cancer is a rare disease, accounting for only 1 % of breast cancer diagnoses in the USA. The current literature suggests that genetic factors including BRCA2 mutations, family history, age, androgen/estrogen imbalance, and environmental exposures may predispose to male breast cancer. In this manuscript, we will review known and possible risk factors for male breast cancer, as well as describe the clinical patterns of the disease.
Literature
1.
Siegel R et al. Cancer statistics, 2014. CA Cancer J Clin. 2014;64(1):9–29.CrossRefPubMed
2.
Jepson AS, Fentiman IS. Male breast cancer. Int J Clin Pract. 1998;52(8):571–6.PubMed
3.
Giordano SH et al. Breast carcinoma in men: a population-based study. Cancer. 2004;101(1):51–7.CrossRefPubMed
4.
Society, A.C. Cancer facts and figures 2015. Atlanta: American Cancer Society; 2015.
5.
Howlader N, Noone AM, Krapcho M, Garshell J, Miller D, Altekruse SF, Kosary CL, Yu M, Ruhl J, Tatalovich Z, Mariotto A, Lewis DR, Chen HS, Feuer EJ, Cronin KA (editors). SEER cancer statistics review, 1975–2011. Bethesda, Maryland: National Cancer Institute.
6.••
Cardoso F, Bartlett J, Giordano S, et al., Characterization of male breast cancer: first results of the EORTC10085/TBCRC/BIG/NABCG International Male BC Program, in 2014 San Antonio Breast Cancer Symposium 2014, European Organization for Research and Treatmento of Cancer: San Antonio, Texas. This study is the largest collection of male breast cancer biologic samples and clinical characteristics to date. All clinical data and pathology were centrally reviewed for 1473 eligible patients who were treated from 1990 to 2010. The authors report on clinical characteristic and overall survival in male breast cancer patients.
7.
Goss PE et al. Male breast carcinoma: a review of 229 patients who presented to the Princess Margaret Hospital during 40 years: 1955–1996. Cancer. 1999;85(3):629–39.CrossRefPubMed
8.•
Masci G et al. Clinicopathological and immunohistochemical characteristics in male breast cancer: a retrospective case series. Oncologist. 2015;20(6):586–92. In this study, Masci et al. evaluated the cliniopathologic characteristics of 97 male breast cancer specimens and found substantial differences than what it typically seen in female breast cancer. Male breast cancer showed higher rates of hormone receptor positivity and lower rates of HER2 overexpression. Furthermore, higher proliferative index and higher grade were associated with shorter overall survival. CrossRefPubMed
9.
Gnerlich JL et al. Poorer survival outcomes for male breast cancer compared with female breast cancer may be attributable to in-stage migration. Ann Surg Oncol. 2011;18(7):1837–44.PubMedCentralCrossRefPubMed
10.
Chung HC et al. Expression of prognostic factors (EGFR, ER) by immunohistochemical staining method in male breast cancer. Yonsei Med J. 1991;32(2):126–30.CrossRefPubMed
11.
Fox SB et al. Oestrogen receptor and epidermal growth factor receptor expression in male breast carcinoma. J Pathol. 1992;166(1):13–8.CrossRefPubMed
12.
Dawson PJ, Paine TM, Wolman SR. Immunocytochemical characterization of male breast cancer. Mod Pathol Off J U S Can Acad Pathol Inc. 1992;5(6):621–5.
13.
Anderson WF et al. Male breast cancer: a population-based comparison with female breast cancer. J Clin Oncol Off J Am Soc Clin Oncol. 2010;28(2):232–9.CrossRef
14.
Arslan UY et al. Outcome of non-metastatic male breast cancer: 118 patients. Med Oncol. 2012;29(2):554–60.CrossRefPubMed
15.
Moore J et al. Prognostic indicators in male breast carcinoma. Breast J. 1998;4(4):261–9.CrossRefPubMed
16.
Leach IH, Ellis IO, Elston CW. c-erb-B-2 expression in male breast carcinoma. J Clin Pathol. 1992;45(10):942.PubMedCentralCrossRefPubMed
17.
Willsher PC et al. Male breast cancer: pathological and immunohistochemical features. Anticancer Res. 1997;17(3C):2335–8.PubMed
18.
Leone JP et al. Prognostic significance of tumor subtypes in male breast cancer: a population-based study. Breast Cancer Res Treat. 2015;152(3):601–9.CrossRefPubMed
19.
Anderson WF et al. Is male breast cancer similar or different than female breast cancer? Breast Cancer Res Treat. 2004;83(1):77–86.CrossRefPubMed
20.
Shak S, Palmer G, Baehner FL, Millward C, Watson D, Sledge Jr GW. Molecular characterization of male breast cancer by standardized quantitative RT-PCR analysis: first large genomic study of 347 male breast cancers compared to 82,434 female breast cancers. J Clin Oncol (Meet Abstr). 2009;27:549.
21.
Jamy O et al. Male breast cancer: a 24 year experience of a tertiary care hospital in Pakistan. Asian Pac J Cancer Prev APJCP. 2015;16(4):1559–63.CrossRefPubMed
22.
Albasri A et al. Histopathological features of breast cancer in Al-Madinah region of Saudi Arabia. Saudi Med J. 2014;35(12):1489–93.PubMedCentralPubMed
23.
Salehi A et al. Survival of male breast cancer in Fars, South of Iran. Iran Red Crescent Med J. 2011;13(2):99–105.PubMedCentralPubMed
24.
Tawil AN et al. Clinicopathologic and immunohistochemical characteristics of male breast cancer: a single center experience. Breast J. 2012;18(1):65–8.CrossRefPubMed
25.
Ndom P et al. A meta-analysis of male breast cancer in Africa. Breast. 2012;21(3):237–41.CrossRefPubMed
26.
Miao H et al. Incidence and outcome of male breast cancer: an international population-based study. J Clin Oncol Off J Am Soc Clin Oncol. 2011;29(33):4381–6.CrossRef
27.
Chavez-Macgregor M et al. Male breast cancer according to tumor subtype and race: a population-based study. Cancer. 2013;119(9):1611–7.PubMedCentralCrossRefPubMed
28.
Sineshaw HM et al. Black/White disparities in receipt of treatment and survival among men with early-stage breast cancer. J Clin Oncol Off J Am Soc Clin Oncol. 2015;33(21):2337–44.CrossRef
29.
O’Malley CD et al. Racial/ethnic differences in survival rates in a population-based series of men with breast carcinoma. Cancer. 2002;94(11):2836–43.CrossRefPubMed
30.
Johnson KC, Pan S, Mao Y. Risk factors for male breast cancer in Canada, 1994–1998. Eur J Cancer Prev Off J Eur Cancer Prev Organ. 2002;11(3):253–63.CrossRef
31.
Ewertz M et al. Risk factors for male breast cancer—a case–control study from Scandinavia. Acta Oncol. 2001;40(4):467–71.CrossRefPubMed
32.
Lenfant-Pejovic MH et al. Risk factors for male breast cancer: a Franco-Swiss case–control study. Int J Cancer. 1990;45(4):661–5.CrossRefPubMed
33.
Brinton LA et al. Prospective evaluation of risk factors for male breast cancer. J Natl Cancer Inst. 2008;100(20):1477–81.PubMedCentralCrossRefPubMed
34.
D’Avanzo B, La Vecchia C. Risk factors for male breast cancer. Br J Cancer. 1995;71(6):1359–62.PubMedCentralCrossRefPubMed
35.
Rosenblatt KA et al. Breast cancer in men: aspects of familial aggregation. J Natl Cancer Inst. 1991;83(12):849–54.CrossRefPubMed
36.
Casagrande JT et al. A case–control study of male breast cancer. Cancer Res. 1988;48(5):1326–30.PubMed
37.
Basham VM et al. BRCA1 and BRCA2 mutations in a population-based study of male breast cancer. Breast Cancer Res BCR. 2002;4(1):R2.CrossRefPubMed
38.
Ottini L et al. BRCA1 and BRCA2 mutation status and tumor characteristics in male breast cancer: a population-based study in Italy. Cancer Res. 2003;63(2):342–7.PubMed
39.
Boyd J et al. Male breast cancer in the hereditary nonpolyposis colorectal cancer syndrome. Breast Cancer Res Treat. 1999;53(1):87–91.CrossRefPubMed
40.
Fackenthal JD et al. Male breast cancer in Cowden syndrome patients with germline PTEN mutations. J Med Genet. 2001;38(3):159–64.PubMedCentralCrossRefPubMed
41.
Ruddy KJ, Winer EP. Male breast cancer: risk factors, biology, diagnosis, treatment, and survivorship. Ann Oncol Off J Eur Soc Med Oncol ESMO. 2013;24(6):1434–43.CrossRef
42.
Holloman WK. Unraveling the mechanism of BRCA2 in homologous recombination. Nat Struct Mol Biol. 2011;18(7):748–54.PubMedCentralCrossRefPubMed
43.
Couch FJ et al. BRCA2 germline mutations in male breast cancer cases and breast cancer families. Nat Genet. 1996;13(1):123–5.CrossRefPubMed
44.
Friedman LS et al. Mutation analysis of BRCA1 and BRCA2 in a male breast cancer population. Am J Hum Genet. 1997;60(2):313–9.PubMedCentralPubMed
45.
Easton DF et al. Cancer risks in two large breast cancer families linked to BRCA2 on chromosome 13q12-13. Am J Hum Genet. 1997;61(1):120–8.PubMedCentralCrossRefPubMed
46.
Thompson D, Easton D. Variation in cancer risks, by mutation position, in BRCA2 mutation carriers. Am J Hum Genet. 2001;68(2):410–9.PubMedCentralCrossRefPubMed
47.
Kwiatkowska E et al. BRCA2 mutations and androgen receptor expression as independent predictors of outcome of male breast cancer patients. Clin Cancer Res Off J Am Assoc Cancer Res. 2003;9(12):4452–9.
48.
Thorlacius S et al. Study of a single BRCA2 mutation with high carrier frequency in a small population. Am J Hum Genet. 1997;60(5):1079–84.PubMedCentralPubMed
49.
Struewing JP et al. Founder BRCA1/2 mutations among male patients with breast cancer in Israel. Am J Hum Genet. 1999;65(6):1800–2.PubMedCentralCrossRefPubMed
50.
Sverdlov RS et al. Genetic analyses of male breast cancer in Israel. Genet Test. 2000;4(3):313–7.CrossRefPubMed
51.
Zhou BB, Elledge SJ. The DNA damage response: putting checkpoints in perspective. Nature. 2000;408(6811):433–9.CrossRefPubMed
52.
Meijers-Heijboer H et al. Low-penetrance susceptibility to breast cancer due to CHEK2(*)1100delC in noncarriers of BRCA1 or BRCA2 mutations. Nat Genet. 2002;31(1):55–9.CrossRefPubMed
53.
Neuhausen S et al. Role of CHEK2*1100delC in unselected series of non-BRCA1/2 male breast cancers. Int J Cancer. 2004;108(3):477–8.CrossRefPubMed
54.
Falchetti M et al. BRCA1/BRCA2 rearrangements and CHEK2 common mutations are infrequent in Italian male breast cancer cases. Breast Cancer Res Treat. 2008;110(1):161–7.CrossRefPubMed
55.
Martinez-Bouzas C et al. CHEK2 1100delC is present in familial breast cancer cases of the Basque Country. Breast Cancer Res Treat. 2007;103(1):111–3.CrossRefPubMed
56.
Caligo MA et al. The CHEK2 c.1100delC mutation plays an irrelevant role in breast cancer predisposition in Italy. Hum Mutat. 2004;24(1):100–1.CrossRefPubMed
57.
Weischer M et al. Increased risk of breast cancer associated with CHEK2*1100delC. J Clin Oncol Off J Am Soc Clin Oncol. 2007;25(1):57–63.CrossRef
58.
Rizzolo P et al. Male breast cancer: genetics, epigenetics, and ethical aspects. Ann Oncol Off J Eur Soc Med Oncol ESMO. 2013;24(8):viii75–82.
59.
Young IE et al. A polymorphism in the CYP17 gene is associated with male breast cancer. Br J Cancer. 1999;81(1):141–3.PubMedCentralCrossRefPubMed
60.
Harnden DG, Maclean N, Langlands AO. Carcinoma of the breast and Klinefelter’s syndrome. J Med Genet. 1971;8(4):460–1.PubMedCentralCrossRefPubMed
61.
Giordano SH. A review of the diagnosis and management of male breast cancer. Oncologist. 2005;10(7):471–9.CrossRefPubMed
62.
Hultborn R et al. Prevalence of Klinefelter’s syndrome in male breast cancer patients. Anticancer Res. 1997;17(6D):4293–7.PubMed
63.
Newman J. Breast cancer in men and mammography of the male breast. Radiol Technol. 1997;69(1):17–28. quiz 29–36.PubMed
64.
Scheike O, Visfeldt J, Petersen B. Male breast cancer. 3. Breast carcinoma in association with the Klinefelter syndrome. Acta Pathol Microbiol Scand A Pathol. 1973;81(3):352–8.
65.
Lynch HT, Watson P, Narod SA. The genetic epidemiology of male breast carcinoma. Cancer. 1999;86(5):744–6.CrossRefPubMed
66.
Evans DB, Crichlow RW. Carcinoma of the male breast and Klinefelter’s syndrome: is there an association? CA Cancer J Clin. 1987;37(4):246–51.CrossRefPubMed
67.
Thomas DB et al. Breast cancer in men: risk factors with hormonal implications. Am J Epidemiol. 1992;135(7):734–48.PubMed
68.
Mester J, Eng C. Cowden syndrome: recognizing and managing a not-so-rare hereditary cancer syndrome. J Surg Oncol. 2015;111(1):125–30.CrossRefPubMed
69.
Ottini L et al. Male breast cancer. Crit Rev Oncol Hematol. 2010;73(2):141–55.CrossRefPubMed
70.
Brinton LA et al. Anthropometric and hormonal risk factors for male breast cancer: male breast cancer pooling project results. J Natl Cancer Inst. 2014;106(3):djt465.PubMedCentralCrossRefPubMed
71.
Hsing AW et al. Risk factors for male breast cancer (United States). Cancer Causes Control CCC. 1998;9(3):269–75.CrossRefPubMed
72.
Brinton LA et al. Prediagnostic sex steroid hormones in relation to male breast cancer risk. J Clin Oncol Off J Am Soc Clin Oncol. 2015;33(18):2041–50.CrossRef
73.
Longcope C et al. Estrogen and androgen dynamics in liver disease. J Endocrinol Investig. 1984;7(6):629–34.CrossRef
74.
Guechot J et al. Sex hormone imbalance in male alcoholic cirrhotic patients with and without hepatocellular carcinoma. Cancer. 1988;62(4):760–2.CrossRefPubMed
75.
Sorensen HT et al. Risk of breast cancer in men with liver cirrhosis. Am J Gastroenterol. 1998;93(2):231–3.CrossRefPubMed
76.
Mills PR et al. Primary biliary cirrhosis: an increased incidence of extrahepatic malignancies? J Clin Pathol. 1982;35(5):541–3.PubMedCentralCrossRefPubMed
77.
Goudie BM et al. Breast cancer in women with primary biliary cirrhosis. Br Med J. 1985;291(6509):1597–8.CrossRef
78.
Wolke AM et al. Malignancy in primary biliary cirrhosis. High incidence of breast cancer in affected women. Am J Med. 1984;76(6):1075–8.CrossRefPubMed
79.
Floreani A et al. Hepatic and extrahepatic malignancies in primary biliary cirrhosis. Hepatology. 1999;29(5):1425–8.CrossRefPubMed
80.
Rubino A, Fissi S, Secreto G. Bilateral breast cancer in a male patient with hepatocellular carcinoma. A case report. Ann Ital Chir. 2008;79(2):117–9.PubMed
81.
Yoneda S et al. Breast cancer developed in a male patient with liver cirrhosis bearing hepatocellular carcinoma. Am J Gastroenterol. 2000;95(2):556–7.PubMed
82.
Sasco AJ, Lowenfels AB, Pasker-de Jong P. Review article: epidemiology of male breast cancer. A meta-analysis of published case–control studies and discussion of selected aetiological factors. Int J Cancer. 1993;53(4):538–49.CrossRefPubMed
83.
Thomas E. Original research: men’s awareness and knowledge of male breast cancer. Am J Nurs. 2010;110(10):32–7. 39–40; quiz 41–2.CrossRefPubMed
84.
Thomas DB et al. Ionizing radiation and breast cancer in men (United States). Cancer Causes Control CCC. 1994;5(1):9–14.CrossRefPubMed
85.
Mabuchi K, Bross DS, Kessler II. Risk factors for male breast cancer. J Natl Cancer Inst. 1985;74(2):371–5.PubMed
86.
Pollan M, Gustavsson P, Floderus B. Breast cancer, occupation, and exposure to electromagnetic fields among Swedish men. Am J Ind Med. 2001;39(3):276–85.CrossRefPubMed
87.
Giordano SH, Buzdar AU, Hortobagyi GN. Breast cancer in men. Ann Intern Med. 2002;137(8):678–87.CrossRefPubMed
88.
Bove FJ et al. Mortality study of civilian employees exposed to contaminated drinking water at USMC Base Camp Lejeune: a retrospective cohort study. Environ Health Glob Access Sci Sour. 2014;13:68.
89.
Cocco P et al. Case–control study of occupational exposures and male breast cancer. Occup Environ Med. 1998;55(9):599–604.PubMedCentralCrossRefPubMed
90.
Feychting M et al. Magnetic fields and breast cancer in Swedish adults residing near high-voltage power lines. Epidemiology. 1998;9(4):392–7.CrossRefPubMed
91.
Stenlund C, Floderus B. Occupational exposure to magnetic fields in relation to male breast cancer and testicular cancer: a Swedish case–control study. Cancer Causes Control CCC. 1997;8(2):184–91.CrossRefPubMed
92.
Matanoski GM, Breysse PN, Elliott EA. Electromagnetic field exposure and male breast cancer. Lancet. 1991;337(8743):737.CrossRefPubMed
93.
Theriault G et al. Cancer risks associated with occupational exposure to magnetic fields among electric utility workers in Ontario and Quebec, Canada, and France: 1970–1989. Am J Epidemiol. 1994;139(6):550–72.PubMed
94.
Guenel P et al. Incidence of cancer in persons with occupational exposure to electromagnetic fields in Denmark. Br J Ind Med. 1993;50(8):758–64.PubMedCentralPubMed
95.
Stalsberg H et al. Histologic types and hormone receptors in breast cancer in men: a population-based study in 282 United States men. Cancer Causes Control CCC. 1993;4(2):143–51.CrossRefPubMed
96.
Wick MR et al. Low-stage carcinoma of the male breast. A histologic, immunohistochemical, and flow cytometric comparison with localized female breast carcinoma. Am J Clin Pathol. 1999;111(1):59–69.PubMed
Image Credits